EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

BCR :: ABL1 Tyrosine Kinase Inhibitors During Pregnancy, a Disproportionality Analysis of Vigibase

Aurélie Cabannes-Hamy iD, Rayan Kabirian iD, Floriane Jochum iD, Kevin Bihan iD, Elise Dumas iD, Florence Coussy iD, Enora Laas iD, Philippe Rousselot iD, Sylvain Choquet, Madalina Uzunov iD, Laurent Salomon iD, Fabien Reyal iD und 2 weitere

Clinical Pharmacology & Therapeutics · 2025

DOI: 10.1002/cpt.3730 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2025. Verfasst von Aurélie Cabannes-Hamy und 13 weiteren Autor:innen. Beteiligte Einrichtung: Hematology, Centre Hospitalier de Versailles Site André Mignot, Le Chesnay-Rocquencourt, France. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Fusion Proteins, bcr-abl, Pregnancy Complications, Neoplastic. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tyrosine kinase inhibitors (TKIs) targeting BCR::ABL1 have greatly improved the survival of patients with chronic myeloid leukemia (CML), and their teratogenicity appears as an important factor for individuals of childbearing potential. This study aims to investigate pregnancy and fetal/newborn adverse outcomes resulting from exposure to BCR::ABL1‐TKIs during pregnancy. For this disproportionality analysis, we used the WHO's global VigiBase up to January 2024, and included reports involving pregnancy, antineoplastic treatment during pregnancy, and cancer. The exposure group consisted of reports mentioning BCR::ABL1‐TKIs at any time during pregnancy. The primary outcome was the reporting odds ratio (ROR) of maternal‐fetal complications in the BCR::ABL1‐TKIs group compared to other anticancer treatments. The analysis included 3,389 reports (TKI = 969; other = 2,420). In the BCR::ABL1‐TKI‐exposed group, the mean age was 28.9 years, and 724 patients (92.2%) were treated for CML. BCR::ABL1‐TKIs were mainly imatinib ( n = 642, 66.3%), nilotinib ( n = 218, 22.5%), and dasatinib ( n = 127, 13.1%) reported without other non‐TKI anticancer agents(92.3%). Compared to other anticancer drugs, overreported outcomes with TKIs included hydrops fetalis (ROR = 13 [95%CI = 1.5–110], P = 0.009), polyhydramnios (ROR = 5 [1.3–20], P = 0.02), and threatened preterm labor (ROR = 10 [1.1–90], P = 0.03). When analyzing specific molecule effects, hydrops fetalis (ROR = 27 [5.4–130], P = 0.001) and polyhydramnios (ROR = 13 [3.3–54], P = 0.004) were overreported with dasatinib. In this large cohort of 969 individuals exposed to TKIs during pregnancy, dasatinib use was associated with most BCR::ABL1‐TKI‐specific toxicities and should be avoided during pregnancy. Fewer or no adverse events were overreported with imatinib and nilotinib.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Kinase InhibitorsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveFusion Proteins, bcr-ablPregnancy Complications, NeoplasticAntineoplastic AgentsHumansFemalePregnancyAdultYoung AdultInfant, NewbornPregnancy OutcomeTyrosine Kinase Inhibitors

Substanzen

Protein Kinase InhibitorsFusion Proteins, bcr-ablAntineoplastic AgentsBCR-ABL1 fusion protein, humanTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Hematology, Centre Hospitalier de Versailles Site André Mignot, Le Chesnay-Rocquencourt, France.
  • Residual Tumor & Response to Treatment Laboratory, RT2Lab, INSERM, U932 Immunity and Cancer, Institut Curie, Université Paris Cité, Paris, France.
  • Department of Gynecology, Strasbourg University Hospital, Strasbourg, France.
  • Department of Pharmacology, Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance Publique - Hôpitaux de Paris (AP-HP), Clinical Investigation Center (CIC-1901), Sorbonne Université, Pitié-Salpê…
  • Paris Pitié-St Antoine Regional Pharmacovigilance Center, Medical Pharmacology Department, APHP Sorbonne University Hospital Group, Paris, France.
  • Department of Mathematics, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.

ORCID-Profile: Aurélie Cabannes-Hamy, Rayan Kabirian, Floriane Jochum, Kevin Bihan, Elise Dumas, Florence Coussy, Enora Laas, Philippe Rousselot, Madalina Uzunov, Laurent Salomon, Fabien Reyal, Anne-Sophie Hamy, Paul Gougis

Zitieren

APA

Cabannes-Hamy, A., Kabirian, R., Jochum, F., Bihan, K., Dumas, E., Coussy, F., Laas, E., Rousselot, P., Choquet, S., Uzunov, M., Salomon, L., Reyal, F., Hamy, A. S., & Gougis, P. (2025). BCR :: ABL1 Tyrosine Kinase Inhibitors During Pregnancy, a Disproportionality Analysis of Vigibase. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3730

Vancouver

Cabannes-Hamy A, Kabirian R, Jochum F, Bihan K, Dumas E, Coussy F, et al. BCR :: ABL1 Tyrosine Kinase Inhibitors During Pregnancy, a Disproportionality Analysis of Vigibase. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.3730

BibTeX
@article{CabannesHamy2025,
  author = {Cabannes-Hamy, Aurélie and Kabirian, Rayan and Jochum, Floriane and Bihan, Kevin and Dumas, Elise and Coussy, Florence and Laas, Enora and Rousselot, Philippe and Choquet, Sylvain and Uzunov, Madalina and Salomon, Laurent and Reyal, Fabien and Hamy, Anne-Sophie and Gougis, Paul},
  title = {BCR :: ABL1 Tyrosine Kinase Inhibitors During Pregnancy, a Disproportionality Analysis of Vigibase},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1002/cpt.3730}
}
Kostenlos starten →